To date, SG has been approved for three indications, including unresectable locally advanced or metastatic TNBC, unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (HR+/HER2- BC), and locally advanced or mUC. This evidence concerns the gene ERBB2 and breast cancer.